These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 15619115)

  • 21. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
    Dominguez C; Prieto L; Valli MJ; Massey SM; Bures M; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD; Monn JA
    J Med Chem; 2005 May; 48(10):3605-12. PubMed ID: 15887967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
    Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
    Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
    Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
    Ferris P; Seward E; Dawson GR
    J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration.
    Tatarczyńska E; Kłodzińska A; Kroczka B; Chojnacka-Wójcik E; Pilc A
    Psychopharmacology (Berl); 2001 Oct; 158(1):94-9. PubMed ID: 11685389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J; Monn JA; Schoepp DD
    J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain.
    Schaffhauser H; Richards JG; Cartmell J; Chaboz S; Kemp JA; Klingelschmidt A; Messer J; Stadler H; Woltering T; Mutel V
    Mol Pharmacol; 1998 Feb; 53(2):228-33. PubMed ID: 9463480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    J Pharmacol Exp Ther; 2001 Aug; 298(2):453-60. PubMed ID: 11454905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
    Monn JA; Prieto L; Taboada L; Pedregal C; Hao J; Reinhard MR; Henry SS; Goldsmith PJ; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Xiang C; Catlow JT; Swanson S; Sanger H; Broad LM; Johnson MP; Knopp KL; Simmons RM; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Feb; 58(4):1776-94. PubMed ID: 25602126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
    Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
    J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
    Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Mayne NG; Wu S; Cockerman SL; Burnett JP; Belegaje R; Bleakman D; Monn JA
    Neuropharmacology; 1997 Jan; 36(1):1-11. PubMed ID: 9144636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Pharmacological Characterization of C4
    Monn JA; Henry SS; Massey SM; Clawson DK; Chen Q; Diseroad BA; Bhardwaj RM; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang XS; Carter JH; Getman BG; Adragni K; Broad LM; Sanger HE; Ursu D; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL; Hao J
    J Med Chem; 2018 Mar; 61(6):2303-2328. PubMed ID: 29350927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.
    Gewirtz JC; Chen AC; Terwilliger R; Duman RC; Marek GJ
    Pharmacol Biochem Behav; 2002 Sep; 73(2):317-26. PubMed ID: 12117585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex.
    Swanson CJ; Perry KW; Schoepp DD
    J Neurochem; 2004 Jan; 88(1):194-202. PubMed ID: 14675163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
    Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
    J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test.
    Shimazaki T; Iijima M; Chaki S
    Eur J Pharmacol; 2004 Oct; 501(1-3):121-5. PubMed ID: 15464070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
    Galici R; Echemendia NG; Rodriguez AL; Conn PJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.
    Marek GJ; Salek AA
    J Pharmacol Exp Ther; 2020 Jul; 374(1):200-210. PubMed ID: 32265323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.